Nuvectis Pharma Stock Alpha and Beta Analysis
| NVCT Stock | USD 4.95 0.15 2.94% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Nuvectis Pharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Nuvectis Pharma over a specified time horizon. Remember, high Nuvectis Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Nuvectis Pharma's market risk premium analysis include:
Beta 2.87 | Alpha (0.46) | Risk 8.63 | Sharpe Ratio (0.01) | Expected Return (0.12) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Nuvectis |
Nuvectis Pharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Nuvectis Pharma market risk premium is the additional return an investor will receive from holding Nuvectis Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Nuvectis Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Nuvectis Pharma's performance over market.| α | -0.46 | β | 2.87 |
Nuvectis Pharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Nuvectis Pharma's Buy-and-hold return. Our buy-and-hold chart shows how Nuvectis Pharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Nuvectis Pharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Nuvectis Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Nuvectis Pharma shares will generate the highest return on investment. By understating and applying Nuvectis Pharma stock market price indicators, traders can identify Nuvectis Pharma position entry and exit signals to maximize returns.
Nuvectis Pharma Return and Market Media
The median price of Nuvectis Pharma for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 6.6 with a coefficient of variation of 19.12. The daily time series for the period is distributed with a sample standard deviation of 1.32, arithmetic mean of 6.92, and mean deviation of 0.93. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Bentsur Ron of 200 shares of Nuvectis Pharma at 14.33 subject to Rule 16b-3 | 08/30/2024 |
2 | Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/05/2024 |
3 | PESG Releases Report on Nuvectis Pharma With Summit Therapeutics Threatening to Dethrone Mercks Keytruda, Nuvectis NXP900 is One to Watch | 09/16/2024 |
4 | Heres Why Were Watching Nuvectis Pharmas Cash Burn Situation | 09/24/2024 |
5 | Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics | 10/23/2024 |
6 | Nuvectis Pharma GAAP EPS of -0.24 beats by 0.01 | 11/05/2024 |
7 | Disposition of 2755 shares by Carson Michael J. of Nuvectis Pharma at 8.159 subject to Rule 16b-3 | 11/07/2024 |
8 | Nuvectis Pharmas VP Michael Carson sells 22.5k in stock | 11/08/2024 |
9 | Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug | 11/14/2024 |
10 | Acquisition by Bentsur Ron of 20000 shares of Nuvectis Pharma at 4.92 subject to Rule 16b-3 | 11/15/2024 |
11 | Acquisition by Enrique Poradosu of 2000 shares of Nuvectis Pharma at 4.99 subject to Rule 16b-3 | 11/19/2024 |
12 | Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma | 11/21/2024 |
About Nuvectis Pharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Nuvectis or other stocks. Alpha measures the amount that position in Nuvectis Pharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2022 | 2023 | 2024 (projected) | Current Ratio | 2.41 | 3.3 | 2.75 | 2.26 | Net Debt To EBITDA | 0.45 | 1.04 | 0.84 | 0.62 |
Nuvectis Pharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Nuvectis Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nuvectis Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Nuvectis Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Nuvectis Pharma. Please utilize our Beneish M Score to check the likelihood of Nuvectis Pharma's management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Nuvectis Pharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.